魯妥珠單抗
化合物
魯妥珠單抗（INN：lumretuzumab；開發代號：RG7116），或譯魯姆妥珠單抗，是一種人源化抗HER3單克隆抗體，設計用於治療癌症。[1][2]
| 單克隆抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | HER3 |
| 臨床資料 | |
| 其他名稱 | RG7116 |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1448327-63-6 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6512H10064N1736O2052S44 |
| 摩爾質量 | 146,916.88 g·mol−1 |
一項Ib/II期研究調查了在第一線治療晚期或轉移性鱗狀非小細胞肺癌（sqNSCLC）患者時，魯妥珠單抗與卡鉑和紫杉醇聯合使用的安全性和臨床活性。[3]
參考資料
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lumretuzumab, American Medical Association.
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 (PDF). WHO Drug Information. 2014, 28 (2).
- ^ Cejalvo, Juan-Miguel; Jacob, Wolfgang; Fleitas Kanonnikoff, Tania; Felip, Enriqueta; Navarro Mendivil, Alejandro; Martinez Garcia, Maria; Taus Garcia, Alvaro; Leighl, Natasha; Lassen, Ulrik; Mau-Soerensen, Morten; Adessi, Celine. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open. 2019, 4 (4). doi:10.1136/esmoopen-2019-000532 （英語）.